In order to evaluate the drug metabolism capacity of individual patients, selective substrate probes have been used in vivo to identify the cytochrome P450 (CYP) isozymes involved in a variety of drug metabolism processes.
Application of the PKCYP-test in Cases of
to induce a fatty liver (CD-fed rats). The rats 11 weeks of age were fed a normal diet for 24 weeks (aged rats). The rats 6 weeks of age were pretreated with MC, as described previously. 4) Control animals, 6 weeks of age, were used without pretreatment. The animal experiments were performed in accordance with the Guidelines for Animal Experiments of Kyoritsu College of Pharmacy.
In Vivo Pharmacokinetic Studies The control, CD-fed, and aged rats were given acetanilide (10 or 20 mg/kg, dissolved in ethanol) or caffeine (10 or 20 mg/kg, dissolved in saline) by intravenous injection. Blood was collected from the jugular vein, and the liver was resected. The blood was centrifuged at 15000ϫg (MX-150, Tomy Seiko Co., Ltd., Tokyo, Japan) for 10 min at 4°C to obtain serum. Serum and liver were stored at Ϫ20 and Ϫ80°C, respectively, until they were assayed. The clearances of acetanilide and caffeine were obtained by moment analysis.
Determination of Serum Protein Binding of Acetanilide and Caffeine
The serum protein binding of acetanilide and caffeine was determined by ultrafiltration using a Centrifree device (Amicon, Inc., Beverly, MA, U.S.A.), as described previously. 4) Determination of Hepatic Blood Flow Rate The hepatic blood flow rate was estimated using a modification of the reported procedure.
12) CD-fed rats had a cannula inserted in the femoral artery and hepatic vein under light ether anesthesia, and indocyanine green (ICG) (2.5 mg/kg loading dose and 2.5 mg/h/kg maintenance dose) was given by injection into the femoral vein. Plasma was obtained from blood samples taken from the femoral artery at 30, 40, 50, and 60 min, and from the hepatic vein at 35, 45, 55, and 65 min after the administration of ICG. The ICG concentration in plasma was measured with a U-3210 Spectrophotometer (Hitachi, Tokyo, Japan) at a wavelength at 800 nm after an 11-fold dilution with distilled water. The hepatic blood flow rate was calculated using the equation developed by Bradley et al. 13) The value of the hepatic blood flow rate in CD-fed rats was high enough not to affect the estimation of intrinsic metabolic clearance (CL int ).
Quantitation of CYP1A2 in Hepatic Microsomes Hepatic microsomes were prepared as previously described. 14) The CYP1A2 level in hepatic microsomes was quantified by Western blotting, as described previously. 4) Briefly, hepatic microsomes derived from the control (2-6 mg protein/lane) and CD-fed (2-32 mg protein/lane) rats were separated by electrophoresis on a 10% SDS-polyacrylamide gel. Rat CYP1A2, purified as previously described, 15) was also applied (0.01-0.04 pmol/lane) as a standard. The separated proteins were then transferred to a nitrocellulose membrane which was then incubated with antibodies. Anti-Syrian hamster CYP1A2, raised in rabbit as previously described, 16) was used as the first antibody. The second antibody was against peroxidase-linked rabbit Ig, isolated from donkeys (Amersham, Aylesbury, U.K.). The antibody against Syrian hamster CYP1A2 was shown to cross-react with rat CYP1A2. 14) To visualize peroxidase activity on the immunoblots, Western Blot Chemiluminescence Reagent (NEN, Boston, MA, U.S.A.) was applied to the nitrocellulose membrane, which was then exposed to a photographic film (Hyper ECL, Amersham, Aylesbury, U.K.) for 30 s. The CYP1A2 protein band identified on the film was quantified densitometrically with an electrophoresis documentation and analysis system (Eastman Kodak, Rochester, NY, U.S.A.), and the CYP1A2 protein content was determined from a standard curve generated using purified rat CYP1A2. In CD-fed rats, no CYP1A2 protein bands could be detected.
Inhibitory Effect of Anti-rat CYP1A1 and CYP1A Antibodies on the Metabolism of Acetanilide and Caffeine in Hepatic Microsomes The assay mixture for acetanilide metabolism contained 0.25 mM acetanilide, 0.67 mg/ml MgCl 2 · 6H 2 O, and 25 mM Tris buffer (pH 8.0) in a final volume of 0.5 ml (for MC-treated rats) or 1.0 ml (for control, CD-fed, and aged rats). Control, CD-fed, aged, and MCtreated rat hepatic microsomes (0.5, 1.0, 0.5, and 0.1 mg, respectively) were preincubated with 50 ml (for MC-treated rats) or 100 ml (for control, CD-fed, and aged rats) anti-rat CYP1A1 or CYP1A antibody for 30 min at room temperature prior to the measurement of acetanilide metabolite formation. Under these conditions, the CYP1A1 or CYP1A activity of all microsomes, irrespective of their origin, was maximally inhibited. Control incubations contained an equivalent amount of preimmune goat (for CYP1A1) or rabbit (for CYP1A) serum proteins. Then, the assay mixture without acetanilide was added, and preincubation was carried out in a shaking bath for 10 min (for control, CD-fed, and aged rats) or 20 min (for MC-treated rats) at 37°C. The reaction was started by the addition of acetanilide, and incubation was carried out in a shaking bath for 10 min (for control, aged, and MC-treated rats) or 20 min (for CD-fed rats) at 37°C. The reaction was halted by the addition of 5 ml ethyl acetate, and the acetanilide metabolites in the samples were assayed.
The assay mixture for caffeine metabolism contained 100 mM [8- 14 C] caffeine, 0.67 mg/ml MgCl 2 · 6H 2 O, and 25 mM Tris buffer (pH 8.0) in a final volume of 0.5 ml. The specific activity of [8- 14 C] caffeine was adjusted to 1924 Bq/nmol by dilution with unlabeled caffeine. Control, CDfed, aged, and MC-treated rat hepatic microsomes (0.125, 0.25, 0.0625, and 0.025 mg, respectively) were preincubated with 50 ml anti-rat CYP1A1 or CYP1A antibody for 30 min at room temperature prior to the measurement of caffeine metabolite formation. Under these conditions, the CYP1A1 or CYP1A activity of all microsomes, irrespective of their origin, was maximally inhibited. Control incubations contained an equivalent amount of preimmune goat (for CYP1A1) or rabbit (for CYP1A) serum proteins. Then, the assay mixture without caffeine was added, and preincubation was carried out in a shaking bath for 10 min (for control and CD-fed rats) or 20 min (for aged and MC-treated rats) at 37°C. The reaction was started by the addition of caffeine, and incubation was carried out in a shaker bath for 10 min (for control, aged, and MC-treated rats) or 20 min (for CDfed rats) at 37°C. The reaction was halted by the addition of 500 ml 20% perchloric acid, and the radioactivity due to each of the caffeine metabolites was measured.
Assay of Acetanilide, Caffeine and Their Metabolites Acetanilide and caffeine in serum and liver were assayed by HPLC, as described previously. 4) Acetanilide metabolites in the samples for inhibition studies of in vitro acetanilide metabolism were assayed by HPLC. In this procedure, 50 ml (for MC-treated rats) or 100 ml (for control, CD-fed, and aged rats) 1 mg/ml phenacetin (internal standard) and 2.5 ml 1 M sodium phosphate buffer (pH 7.0) were added to each sample, followed by vortexing and centrifugation at 700ϫg (RLX-105, Tomy Seiko Co., Ltd., Tokyo, Japan) for 5 min at room temperature. The ethyl acetate phase was evaporated, and the residue was redissolved in 250 ml HPLC mobile phase and filtered through a 0.45 mm filter (4 mm Millex-LH, Nihon Millipore, Ltd., Tokyo, Japan). Following this, 30 ml of filtrate was subjected to HPLC. A calibration curve was constructed using 0.67 mg/ml MgCl 2 · 6H 2 O, 25 mM Tris buffer (pH 8.0) with concentrated p-hydroxyacetanilide solution to give standard solutions of 0.025, 0.05, 0.1, 0.2, and 0.4 mg/ml in a final volume of 0.5 ml (for MC-treated rats) or 1.0 ml (for control, CD-fed, and aged rats). Standards were then submitted to the extraction procedure described above. A calibration curve was obtained by plotting the peak-area on the ordinate axis versus the respective drug concentrations on the abscissa. The HPLC system consisted of a pump (Programmable pump, Model 307, Gilson, Middleton, WI, U.S.A.), an autoinjector (Model 234, Gilson, Middleton, WI, U.S.A.), a variable wavelength UV detector (Programmable detector Model 118 (UV/VIS), Gilson, Middleton, WI, U.S.A.), a recorder (Chromatocorder 21, System Instruments, Tokyo, Japan), and a column oven (655A-52 column oven, Hitachi, Tokyo, Japan). Separation was achieved on a C18 reversedphase column (250 mmϫ4.6 mm i.d., particle size 5 mm, Capcell Pak C18 UG120 S-5 mm, Shiseido, Tokyo, Japan) at a column temperature of 40°C. The mobile phase consisted of 20 : 80 (v/v) acetonitrile : 20 mM acetic acid (adjusted to pH 4.0 with NH 4 OH), 3) at a flow rate of 0.5 ml/min, and the column elute was monitored at 254 nm. The retention times for p-hydroxyacetanilide, acetanilide, and phenacetin were 7.7, 17.3, and 29.3 min, respectively. The lower limit of quantification was 0.025 mg/ml.
To measure the radioactivity of caffeine metabolites in the samples from the inhibition studies of in vitro caffeine metabolism, they were separated by HPLC. Theobromine, theophylline, 1,7-dimethylxanthine, and 1,3,7-trimethyluric acid (internal standard) were added to each sample, followed by vortexing and centrifugation at 15000ϫg (M200-IVD, Sakuma, Tokyo, Japan) for 10 min at 4°C. The supernatant was filtered through a 0.45 mm filter, and the 400 ml filtrate was subjected to HPLC. The HPLC conditions were as follows: instruments, a Shimadzu LC-9A liquid chromatograph equipped with a SPD-6A spectrophotometoric detector, a SCL-6B system controller, a data processor (Chromatopac C-R4A), and a CTO-6A column oven; the HPLC column used was the same as that for the analysis of the acetanilide metabolite; column temperature, 40°C; the mobile phase was a linear gradient of methanol (10-50% (v/v)) containing 0.035% (v/v) acetic acid; flow rate, 0.8 ml/min; the absorbance wavelength was set at 280 nm. The retention times for theobromine, 1,7-dimethylxanthine, theophylline, and 1,3,7-trimethyluric acid, and caffeine were 11.6, 14.0, 14.8, 16.0, and 17.7 min, respectively. Each metabolite fraction was mixed with 5 ml Clear-sol I (Nacalai Tesque, Kyoto, Japan) and counted using a liquid scintillation counter (Beckman LS 5801, Beckman Instruments, U.S.A.).
Theoretical Basis for Determination of qg 4)
We used a well-stirred model to describe the hepatic metabolism of acetanilide and caffeine, as described in a previous report. Briefly, as described elsewhere, 17) the CL int is purely a measure of enzyme activity towards a drug and is not influenced by other physiological factors associated with liver clearance, such as hepatic blood flow or drug binding within the blood matrix.
The rate of metabolism in vivo (v) can be expressed as follows:
where C L,f is the free concentration (not bound to macromolecules) of drug within the hepatic vein. Let us assume that the drug is metabolized by a single CYP isozyme. From a biochemical viewpoint, under linear conditions, the CL int can be considered in terms of the enzyme parameters of the Michaelis-Menten relationship shown in Eq. 2. (2) Where V max,vitro is the in vitro maximal rate of metabolism and K m,vitro is the in vitro Michaelis constant for the drug-enzyme interaction. A-CYP vivo is the in vivo amount of CYP and C E is the drug concentration at the enzyme site.
From this, a relationship between CL int and A-CYP vivo can be derived as follows: (3) Generally, the free concentration of drug within the hepatic vein is assumed to be C E . However, if there is a concentration gradient in vivo (qg) between C E and C L,f , this equation can be rearranged to determine the A-CYP vivo . (4) Although the above equation allows estimation of the individual A-CYP vivo in patients, a preliminary evaluation of qg is necessary. The qg value may be defined as follows, using a standard procedure: (5) Since the qg value cannot be determined practically in vivo, the measured values of CL int , K m,vitro , V max,vitro , and A-CYP vivo may be used to define it.
If the probe or drug is metabolized solely by the liver, the total body clearance (CL tot ) can be expressed as follows: (6) where Q h is the hepatic blood flow rate and f p is the unbound fraction of drug in plasma.
Moreover, the CL int can be expressed as the sum of the CL int of each CYP isozyme. Therefore, qg and A-CYP vivo , and CL int of each CYP isozyme can be expressed as follows: 
(8) (9) where f CYP is the contribution of each CYP isozyme. Figs. 1 and 2 , respectively. Since the body weight differed significantly among these rat models (Table 1) , the total doses of acetanilide and caffeine were determined over a 5-fold range. The acetanilide and caffeine profiles suggest linear pharmacokinetics, so the CL tot was determined under linear conditions. The results of linear model-independent moment analysis are given in Tables 1  and 2 . The CL tot of acetanilide in CD-fed and aged rats fell to about 20 and 30% of that in control rats, respectively, and the differences were statistically significant. The CL tot of caffeine in CD-fed and aged rats also fell to about 20 and 30% of that in control rats, respectively. A reduction in the CL tot of caffeine in aged rats agreed with a previous report. 18) Although no distribution phase was observed following the administration of acetanilide and caffeine in control rats, it took 30 min for distribution in CD-fed and aged rats.
RESULTS

Comparison of the Pharmacokinetics of Acetanilide and Caffeine in Control, CD-fed, and Aged Rats
The physiological data for the acetanilide-and caffeinetreated rats used in this study are also summarized in Tables  1 and 2 , respectively. There were no significant differences in f p or the volume of distribution at a steady-state (V d,ss ) for acetanilide and caffeine between the control and CD-fed or aged rats.
Estimation of the Contribution of CYP1A2 to the Hepatic Microsomal Metabolic Activity for Acetanilide and Caffeine in Control, CD-fed, Aged, and MC-treated Rats
The contribution of CYP1A2 to hepatic microsomal acetanilide and caffeine metabolism in control, CD-fed, aged, and MC-treated rats was estimated using anti-rat CYP1A1 and CYP1A antibodies. The effects of anti-rat CYP1A1 and CYP1A antibodies on acetanilide and caffeine hepatic microsomal metabolism in control, CD-fed, aged, and MC-treated rats are shown in Table 3 . In all rat models, the hepatic microsomal metabolism of acetanilide and caffeine was significantly inhibited by anti-rat CYP1A antibody. There were relatively small differences in the inhibitory effect of anti-rat CYP1A1 antibody on the hepatic microsomal metabolism of acetanilide and caffeine among these rat models. In the case of acetanilide, hepatic microsomal metabolism in CD-fed and aged rats was also inhibited by anti-rat CYP1A1 antibody. On the other hand, an effect of anti-rat CYP1A1 antibody on caffeine hepatic microsomal metabolism was seen in CD-fed and MC-treated rats. The contribution of CYP1A2 to the hepatic microsomal metabolic activity for acetanilide and caffeine in control, CD-fed, aged, and MC-treated rats is listed in Table 3 . The contribution of CYP1A2 to hepatic microsomal acetanilide and caffeine metabolism in CD-fed and aged rats was reduced.
Prediction of Hepatic CYP1A2 Content in CD-fed, Aged, and MC-treated Rats Because no unchanged acetanilide was detected in the urine (data not shown), the metabolism of acetanilide essentially involves only the liver. Therefore, the CL int can be estimated from CL tot , f p , and Q h , 19, 20) as follows:
For each CYP isozyme, the intrinsic clearance can be obtained by multiplying the f CYP by the apparent CL int . Therefore, the qg value of acetanilide for CYP1A2 in control rats can be estimated according to Eq. 7 as follows:
where qg is the value when the drug is assumed to be metabolized only by this CYP isozyme, and f CYP is assumed to be unity. The reported values of the K m,vitro and V max,vitro of acetanilide were used in this estimation. 21) Assuming that the qg value is similar in control, CD-fed, aged, and MC-treated rats, the A-CYP vivo in CD-fed, aged, and MC-treated rats may be predicted from Eq. 8 as follows:
Since the standard deviation of the f CYP was the largest among the parameters used in the prediction, we took account of this when making any predictions. As far as MCtreated rats are concerned, values of CL tot and f p have been previously reported.
4) The predicted A-CYP vivo in MC-treated rats agreed with the observed value of 85.4 nmol/kg.
4)
Prediction of Caffeine Clearance Mediated by CYP1A2 in CD-fed, Aged, and MC-treated Rats Since the contribution of CYP1A2 to the metabolism of caffeine was fluctuated in CD-fed, aged, and MC-treated rats, we tried to predict the clearance of caffeine mediated by CYP1A2 by applying the qg value. In a similar manner to acetanilide, the clearance of caffeine mediated by CYP1A2 in control rats was used to determine the qg value of caffeine for CYP1A2.
The reported values of the K m,vitro and V max,vitro of caffeine were used. 22) Assuming that the qg value is similar in control, CD-fed, aged, and MC-treated rats, caffeine clearance mediated by CYP1A2 (CL CYP1A2 ) in CD-fed, aged, and MC-treated rats can be predicted by using A-CYP vivo , which was predicted from the acetanilide clearance mediated by CYP1A2 according to Eq. 9 as follows: Hence, the predicted CL CYP1A2 was smaller than the observed value (Table 4) . -3) . b) The activity of acetanilide in control, CD-fed, aged, and MC-treated rats was 200Ϯ26, 22Ϯ10, 159Ϯ19, and 835Ϯ13 pmol/min/mg, respectively. The activity of caffeine in control, CD-fed, aged, and MCtreated rats was 25.1Ϯ5.4, 4.90Ϯ1.74, 9.56Ϯ0.26, and 129Ϯ14 pmol/min/mg, respectively. c) Since the inhibitory capacity of anti-rat CYP1A1 towards CYP1A1 was 65%, the activities which were inhibited by anti-rat CYP1A1 were corrected by this value. d) Not inhibited. e) Cϭ{(100ϪB)Ϫ(100ϪA)}/100 (AϹ100), Cϭ (100ϪB)/100 (AϾ100).
CL CYP1A2 in aged ratsϭ · (0.62Ϯ0.16) · 0.59 ϭ0.49Ϯ0.13 ml/min/kg Hence, the predicted CL CYP1A2 agreed with the observed value ( Table 4) . Hence, the predicted CL CYP1A2 agreed with the observed value ( Table 4) .
DISCUSSION
In the case of drugs which are metabolized by more than two CYP isozymes, the intrinsic metabolic clearance is expressed as the sum of the intrinsic metabolic clearance of each CYP isozyme. It is important to confirm that the PKCYP-test can be applied to each CYP isozyme. Initially, we examined the PKCYP-test with regard to CYP1A2.
In the present study, we examined the application of the PKCYP-test to the clearance of acetanilide and caffeine mediated by CYP1A2 by using rat models in which the level of the CYP enzyme is reduced. In CD-fed and aged rats, the contribution of CYP1A2 to acetanilide and caffeine metabolism was less than that in the control rats (Table 3) . It has been reported that the amount of CYP is reduced in CD-fed and aged rats, and the degree of reduction in each CYP is regulated in a different way. [8] [9] [10] [11] Therefore, it seems that the content of each CYP isozyme in CD-fed and aged rats might be different from that in control rats, and the contribution of CYP isozymes, except for CYP1A2, to acetanilide and caffeine metabolism could not be neglected in these rat models.
The predicted A-CYP vivo corresponding to CYP1A2 from the clearance of acetanilide, according to Eq. 8 in CD-fed and aged rats, was 10 and 15% of the control rats, respectively. In CD-fed rats, because of the detection limit of the assay method, the observed value of A-CYP vivo could not be obtained by Western blotting. Consequently, it was impossible to confirm whether the predicted and observed A-CYP vivo values agreed or not. However, the clearance of caffeine mediated by CYP1A2 could be predicted by the PKCYP-test using the predicted A-CYP vivo .
In aged rats, the predicted clearance of caffeine mediated by CYP1A2, which was estimated from the predicted A-CYP vivo , agreed with the observed value (Table 4) . On the other hand, in CD-fed rats, the predicted clearance of caffeine mediated by CYP1A2 was smaller than the observed value ( Table 4 ). The excretion of unchanged acetanilide and caffeine into the urine in CD-fed rats was negligible (data not shown). Because of the detection limit of the assay method, the effect of anti-rat CYP1A1 and CYP1A antibodies on acetanilide and caffeine metabolism in CD-fed rat liver microsomes could not be estimated under linear conditions. Therefore, this difference may be due to an error in the estimated contribution of CYP1A2 to acetanilide and caffeine metabolism.
In MC-treated rats, the error in the predicted A-CYP vivo and clearance of caffeine was 1.5-and 1.2-fold greater than the measured values, respectively, assuming that acetanilide and caffeine are metabolized only by CYP1A2. 4) On the other hand, the predicted values both of A-CYP vivo and the clearance of caffeine using the present method in MC-treated rats agreed well with the measured values ( Table 4 ).
In conclusion, we were able to show that the PKCYP-test can be applied to the CYP1A2 for drugs metabolized by multiple CYP isozymes. By using the different qg values for acetanilide and caffeine estimated in the control rats, the A-CYP vivo in CD-fed, aged, and MC-treated rats could be predicted. If there are specific probes for each CYP isozyme, the CL tot of drugs which are metabolized by multiple CYP isozymes can be predicted by the PKCYP-test. In the future, it will be possible to measure the f CYP in a search for each individual enzymatic activity following the coadministration of each specific probe, as is the case in a "cocktail" study. 4) corrected by the present method.
